original ) (raw )Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro
Alison Todd
Cancer research, 2001
View PDFchevron_right
Inhibitors of farnesyl:protein transferase—A possible cancer chemotherapeutic
Daniele Leonard
1996
View PDFchevron_right
Farnesyl Transferase Inhibitors as Potential Anticancer Agents
Sounak Bagchi
Mini Reviews in Medicinal Chemistry, 2018
View PDFchevron_right
Tricyclic Farnesyl Protein Transferase Inhibitors: Crystallographic and Calorimetric Studies of Structure−Activity Relationships †
Hung Le
Journal of Medicinal Chemistry, 1999
View PDFchevron_right
Structure−Activity Relationship of 3-Substituted N -(Pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11 H -benzo[5,6]cyclohepta[1,2- b ]pyridin-11-ylidene)- piperidine Inhibitors of Farnesyl-Protein Transferase: Design and Synthesis of in Vivo Active Antitumor Compounds
Ming Liu , Amin Nomeir
Journal of Medicinal Chemistry, 1997
View PDFchevron_right
Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer
Melanie Valenti
Clinical Cancer Research
View PDFchevron_right
Novel Tricyclic Inhibitors of Farnesyl Protein Transferase
George Njoroge
Journal of Biological Chemistry, 1995
View PDFchevron_right
NMR studies of novel inhibitors bound to farnesyl-protein transferase
Charles Omer
Protein Science, 2008
View PDFchevron_right
Conformation of a novel tetrapeptide inhibitor NH2-d-Trp-d-Met-Phe(pCl)-Gla-NH2 bound to farnesyl-protein transferase
A. Pessi
Journal of Peptide Research, 1999
View PDFchevron_right
Potent, Selective, and Orally Bioavailable Tricyclic Pyridyl Acetamide N -Oxide Inhibitors of Farnesyl Protein Transferase with Enhanced in Vivo Antitumor Activity
George Njoroge
Journal of Medicinal Chemistry, 1998
View PDFchevron_right
Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies
Judith Karp
Seminars in Hematology, 2001
View PDFchevron_right
Potent and Selective Farnesyl Transferase Inhibitors
Juozas Domarkas
Journal of Medicinal Chemistry, 2004
View PDFchevron_right
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units
Elzbieta Izbicka
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 1999
View PDFchevron_right
Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase
Christopher Dinsmore
Bioorganic & Medicinal Chemistry Letters, 1999
View PDFchevron_right
Farnesyl Diphosphate-Based Inhibitors of Ras Farnesyl Protein Transferase
Veeraswamy Manne
Journal of Medicinal Chemistry, 1995
View PDFchevron_right
Preparation of a clinically investigated ras farnesyl transferase inhibitor
David Askin
Journal of Heterocyclic Chemistry, 2003
View PDFchevron_right
The synthesis and biological evaluation of a series of potent dual inhibitors of farnesyl and geranyl-Geranyl protein transferases
Michelle Ellis-Hutchings
Bioorganic & Medicinal Chemistry Letters, 2002
View PDFchevron_right
Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models
Charles Omer
Cancer research, 2001
View PDFchevron_right
Streamlined Processes for the Synthesis of a Farnesyl Transferase Inhibitor Drug Candidate
Karl Ng
Organic Process Research & Development, 2004
View PDFchevron_right
Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?
Fadlo Khuri
Endocrine Related Cancer, 2004
View PDFchevron_right
Synthesis and evaluation of a novel series of farnesyl protein transferase inhibitors as non-peptidic CAAX tetrapeptide analogues
Michel Cubas Perez
Bioorganic & Medicinal Chemistry Letters, 2003
View PDFchevron_right
The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein
Christopher Casciano
Cancer research, 2001
View PDFchevron_right